Literature DB >> 23063352

Prediction of metastatic breast cancer in non-sentinel lymph nodes based on metalloprotease-1 expression by the sentinel lymph node.

Noemí Eiró1, Luis O González, Sara Atienza, José M González-Quintana, Nana Beridze, Belen Fernandez-Garcia, Román Pérez-Fernández, Tomás García-Caballero, José Schneider, Francisco J Vizoso.   

Abstract

AIMS: Sentinel lymph node (SLN) biopsy is the current standard axillary approach for patients with clinically node-negative breast cancer. If the SLN is positive, is still also standard in most centres to proceed with a complete axillary dissection to predict the remaining nodes affectation, despite of SLN is the only positive lymph node in 50-68% of cases. If we could identify them, these patients could be spared a complete axillary dissection.
METHODS: Elevated expression of specific matrix metalloproteases (MMPs) and their inhibitors (TIMPs) by stromal mononuclear inflammatory cells (MICs) of primary tumours is significantly associated with distant metastasis development in breast cancer. In the present study we first identified candidate MMPs/TIMPs associated with axillary metastasis in a preliminary group (n=50), and subsequently examined the potential of their expression in the SLN for predicting the status of the remaining nodes, in 105 patients with intraoperative SLN-assessment.
RESULTS: MMP-1 expression by MICs from SLNs was significantly associated with metastatic spread to non-SLNs. Moreover, in all cases with negative MMP-1 expression by MICs from SLNs, the remaining non-SLNs were not affected (p<0.0001). Therefore, we demonstrate that MMP-1 expression by MICs from SLNs had 100% sensitivity, 100% negative-predictive value and 61.5% specificity to predict non-SLNs status.
CONCLUSION: This is the first time that tumour spread to the remaining axillary nodes has been predicted from molecular features of the SLN(s). If confirmed in larger studies, patients could be spared the morbidity associated with an unnecessary complete lymphadenectomy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063352     DOI: 10.1016/j.ejca.2012.09.019

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  6 in total

1.  Cancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13.

Authors:  Juan Sendon-Lago; Samuel Seoane; Noemi Eiro; Maria A Bermudez; Manuel Macia; Tomas Garcia-Caballero; Francisco J Vizoso; Roman Perez-Fernandez
Journal:  Breast Cancer Res       Date:  2014-12-20       Impact factor: 6.466

2.  Molecular biomarkers screened by next-generation RNA sequencing for non-sentinel lymph node status prediction in breast cancer patients with metastatic sentinel lymph nodes.

Authors:  Feng Liang; Hongzhu Qu; Qiang Lin; Yadong Yang; Xiuyan Ruan; Bo Zhang; Yi Liu; Chengze Yu; Hongyan Zhang; Xiangdong Fang; Xiaopeng Hao
Journal:  World J Surg Oncol       Date:  2015-08-28       Impact factor: 2.754

3.  MMP1 and MMP11 Expression in Peripheral Blood Mononuclear Cells upon Their Interaction with Breast Cancer Cells and Fibroblasts.

Authors:  Noemi Eiro; Sandra Cid; Nuria Aguado; María Fraile; Nagore de Pablo; Berta Fernández; Francisco Domínguez; Luis O González; Francisco J Vizoso
Journal:  Int J Mol Sci       Date:  2020-12-31       Impact factor: 5.923

4.  Matrix metalloproteinase‑1 expression is regulated by HIF‑1‑dependent and epigenetic mechanisms and serves a tumor‑suppressive role in gastric cancer progression.

Authors:  Kotaro Ito; Yoshihiko Kitajima; Keita Kai; Shohei Matsufuji; Kohei Yamada; Noriyuki Egawa; Hiroshi Kitagawa; Keiichiro Okuyama; Tomokazu Tanaka; Hirokazu Noshiro
Journal:  Int J Oncol       Date:  2021-11-05       Impact factor: 5.650

5.  Application of the Machine-Learning Model to Improve Prediction of Non-Sentinel Lymph Node Metastasis Status Among Breast Cancer Patients.

Authors:  Qian Wu; Li Deng; Ying Jiang; Hongwei Zhang
Journal:  Front Surg       Date:  2022-04-25

6.  Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer.

Authors:  Noemí Eiró; Iván Pidal; Belen Fernandez-Garcia; Sara Junquera; Maria L Lamelas; José M del Casar; Luis O González; Alfonso López-Muñiz; Francisco J Vizoso
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.